Region:
World
Category:
Society

'Highly likely' BioNTech vaccine works against mutant coronavirus strain

  • BioNTech’s CEO Uğur Şahin says he is confident vaccine can ‘bash the virus over the head’
    Vaccine scientist: virus will be with us for 10 years BioNTech’s CEO Uğur Şahin says he is confident vaccine can ‘bash the virus over the head’
Region:
World
Category:
Society
Publication date:
Print article

BioNTech’s CEO Uğur Şahin says he is confident vaccine can ‘bash the virus over the head’.
Vaccine scientist: virus will be with us for 10 years.

Today the co-founder said even if it didn’t work, the vaccine could be adapted in six weeks.

BioNTech’s CEO Uğur Şahin said:

Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant.

In principle the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation - we could be able to provide a new vaccine technically within six weeks.

Sahin said the variant detected in Britain has nine mutations, rather than just one as is usually common.

Nevertheless, I have voiced confidence that the vaccine developed with Pfizer would be efficient because it “contains more than 1,000 amino acids, and only nine of them have changed, so that means 99 percent of the protein is still the same”.

He said tests are being run on the variant, with results expected in two weeks. I have added:

We have scientific confidence that the vaccine might protect but we will only know it if the experiment is done ... we will publish the data as soon as possible.

The scientist behind the first Covid-19 vaccine to clear interim clinical trials says he is confident his product can “bash the virus over the head” and put an end to the pandemic that has held the world hostage in 2020.

The German company BioNTech and the US pharmaceutical giant Pfizer announced via a press release on Monday that their jointly developed vaccine candidate had outperformed expectations in the crucial phase 3 trials, proving 90% effective in stopping people from falling ill.

However, the lack of full data sets from the ongoing trials has left unanswered the question of whether the vaccine is also effective for those with asymptomatic infections.



In his first interview with a British newspaper, BioNTech’s chief executive, Uğur Şahin, told the Guardian he was optimistic. “If the question is whether we can stop this pandemic with this vaccine, then my answer is: yes, because I believe that even protection only from symptomatic infections will have a dramatic effect,” Şahin said in a Zoom call from his home in Mainz.

Until Monday’s trial results were revealed, the scientist said, he wasn’t sure whether his vaccine would trigger a strong enough reaction from the human immune system. “It was possible that the virus isn’t really targeted by the vaccine, finds its way into the cells and continues to make people ill. We now know that vaccines can beat this virus.”